SG11201804629XA - Compositions and methods for assessing the risk of cancer occurrence - Google Patents

Compositions and methods for assessing the risk of cancer occurrence

Info

Publication number
SG11201804629XA
SG11201804629XA SG11201804629XA SG11201804629XA SG11201804629XA SG 11201804629X A SG11201804629X A SG 11201804629XA SG 11201804629X A SG11201804629X A SG 11201804629XA SG 11201804629X A SG11201804629X A SG 11201804629XA SG 11201804629X A SG11201804629X A SG 11201804629XA
Authority
SG
Singapore
Prior art keywords
international
rule
risk
pct
iii
Prior art date
Application number
SG11201804629XA
Inventor
Jean-François Floch
Original Assignee
Syncerus S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncerus S A R L filed Critical Syncerus S A R L
Publication of SG11201804629XA publication Critical patent/SG11201804629XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 1111111111111111111111 OE III OE III II III IV OE 11111111111111111111111111111111111111 (10) International Publication Number WO 2017/114973 Al WIPO I PCT (43) International Publication Date 6 July 2017 (06.07.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KR KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: (51) International Patent Classification: GO1N 33/574 (2006.01) C07K 16/30 (2006.01) C07K 16/26 (2006.01) G01N 33/74 (2006.01) (21) International Application Number: PCT/EP2017/050034 (22) International Filing Date: 2 January 2017 (02.01.2017) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 15307190.7 31 December 2015 (31.12.2015) 16305133.7 5 February 2016 (05.02.2016) EP EP (71) Applicant: SYNCERUS S.A R.L. [LU/LU]; 11, Cote d'Eich, 1450 Luxembourg (LU). (72) Inventor: FLOCH, Jean-Francois; Château Bois de la Roche, 29610 Garlan (FR). (74) Agent: REGIMBEAU; 20, me de Chazelles, 75847 Paris Cedex 17 (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: COMPOSITIONS AND METHODS FOR ASSESSING THE RISK OF CANCER OCCURRENCE (57) : The present invention provides a method for evaluating the risk of occurrence of cancer in an individual.
SG11201804629XA 2015-12-31 2017-01-02 Compositions and methods for assessing the risk of cancer occurrence SG11201804629XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307190 2015-12-31
EP16305133 2016-02-05
PCT/EP2017/050034 WO2017114973A1 (en) 2015-12-31 2017-01-02 Compositions and methods for assessing the risk of cancer occurrence

Publications (1)

Publication Number Publication Date
SG11201804629XA true SG11201804629XA (en) 2018-07-30

Family

ID=57821944

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804629XA SG11201804629XA (en) 2015-12-31 2017-01-02 Compositions and methods for assessing the risk of cancer occurrence

Country Status (17)

Country Link
US (2) US11085924B2 (en)
EP (1) EP3397965A1 (en)
JP (1) JP6940505B2 (en)
KR (1) KR102620651B1 (en)
CN (2) CN114705858A (en)
AU (1) AU2017204683B2 (en)
BR (1) BR112018013269A2 (en)
CA (1) CA3009768A1 (en)
CL (1) CL2018001788A1 (en)
CO (1) CO2018007621A2 (en)
EA (1) EA201891478A1 (en)
IL (1) IL260301A (en)
MA (1) MA43550A (en)
MX (1) MX2018008175A (en)
SG (1) SG11201804629XA (en)
TN (1) TN2018000197A1 (en)
WO (1) WO2017114973A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018242152B2 (en) 2017-03-30 2022-05-12 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
KR102616819B1 (en) 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. Compositions and methods for treating lung cancer
CA3085067A1 (en) 2017-12-08 2019-06-13 Ecs-Biotracker Sarl Radiolabeled progastrin in cancer diagnosis
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
KR20200144541A (en) * 2018-02-27 2020-12-29 이씨에스-프로가스트린 에스에이 Progastrin as a biomarker for immunotherapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR20050085971A (en) 1995-04-27 2005-08-29 아브게닉스, 인크. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
CN101368966A (en) * 2008-04-29 2009-02-18 北京科美东雅生物技术有限公司 Chemical luminescence immune assay determination reagent kit for gastrin releasing peptide precursor
CN102791735B (en) * 2009-10-16 2016-05-18 瑟维尔实验室 Monoclonal antibody of anti-progastrin and uses thereof
AU2014203017B2 (en) * 2009-10-16 2017-02-02 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
KR101570404B1 (en) 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 Prophylaxis of colorectal and gastrointestinal cancer
AU2011284908B2 (en) 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
EP2715364A1 (en) * 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia

Also Published As

Publication number Publication date
EP3397965A1 (en) 2018-11-07
WO2017114973A1 (en) 2017-07-06
US11085924B2 (en) 2021-08-10
JP2019505783A (en) 2019-02-28
CO2018007621A2 (en) 2018-10-22
KR20180093973A (en) 2018-08-22
TN2018000197A1 (en) 2019-10-04
CN108700586A (en) 2018-10-23
BR112018013269A2 (en) 2018-12-11
CA3009768A1 (en) 2017-07-06
AU2017204683A1 (en) 2018-06-21
CN114705858A (en) 2022-07-05
AU2017204683B2 (en) 2023-03-16
US20210373027A1 (en) 2021-12-02
KR102620651B1 (en) 2024-01-04
US20190011452A1 (en) 2019-01-10
IL260301A (en) 2018-08-30
CL2018001788A1 (en) 2018-09-21
MA43550A (en) 2018-11-07
EA201891478A1 (en) 2019-01-31
MX2018008175A (en) 2019-02-20
JP6940505B2 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804629XA (en) Compositions and methods for assessing the risk of cancer occurrence
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908088RA (en) Antibodies against pd-l1
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201909011PA (en) Niraparib compositions
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201408460UA (en) Inhibitors of the mir-15 family of micro-rnas
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909498XA (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy